Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis

Arthritis Rheum. 1999 Sep;42(9):1894-7. doi: 10.1002/1529-0131(199909)42:9<1894::AID-ANR14>3.0.CO;2-V.


Objective: To assess the efficacy of ciprofloxacin in the treatment of reactive arthritis (ReA) and anterior uveitis (AU) in a double-blind, randomized, placebo-controlled trial.

Methods: Seventy-two patients participated in this study, 56 with ReA and 42 with AU (26 patients had both ReA and AU). Ciprofloxacin (750 mg twice a day) was administered for 12 months with a 12-month followup. End points of the study included time to disease relapse and measures of disease severity.

Results: There was no difference between groups in time to disease relapse, joint inflammation, number of joints and enthesis involved in patients with ReA, or signs and symptoms of AU.

Conclusion: Long-term treatment of ReA and AU with ciprofloxacin made no statistically significant difference to the natural history of these diseases or their severity.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / therapeutic use*
  • Arthritis, Reactive / drug therapy*
  • Ciprofloxacin / therapeutic use*
  • Double-Blind Method
  • Female
  • HLA-B27 Antigen / blood
  • Humans
  • Male
  • Patient Dropouts
  • Prohibitins
  • Recurrence
  • Severity of Illness Index
  • Time Factors
  • Uveitis, Anterior / drug therapy*


  • Anti-Infective Agents
  • HLA-B27 Antigen
  • PHB2 protein, human
  • Prohibitins
  • Ciprofloxacin